Boston Scientific (BSX) said Monday it has agreed to buy medical device company Intera Oncology for an undisclosed sum.
The deal, which will likely close in H1 2025, is expected to have an immaterial effect on adjusted earnings in 2025 and be more dilutive on a GAAP basis owing to acquisition-related net charges and amortization expense, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments